Scholarlink

Purpose of the Review <p>Erectile dysfunction (ED) is a highly prevalent disease, affecting over 24% of men in the United States. Factors such as privacy and accessibility often act as barriers to care for patients. With the emergence of telemedicine, direct-to-consumer (DTC) platforms have become popular avenues for patients to seek care. These platforms are especially attractive to patients with ED due to their promises of providing discrete and convenient care. Phosphodiesterase type 5 (PDE5) inhibitors remain the most commonly prescribed therapy for ED. This review evaluates recent literature over the past five years to better understand the economics of PDE5 inhibitors offered through DTC platforms.</p> Recent Findings <p> Studies have shown that while DTC companies offer convenience, these medications are offered at a significantly marked up price compared to more conventional means, such as an in-person clinical visit and brick and mortar pharmacies.</p> Summary <p> While DTC platforms offer a promising model for improving access to ED care, their economic trade-offs and clinical limitations must be considered. Ongoing research and transparent pricing are needed to ensure that all patients with ED can make informed choices that best meet their clinical and economic needs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Direct-to-Consumer Erectile Dysfunction Medications: is the Convenience Worth the Cost?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月30日

查看全文
  • Michelle K. Li,
  • Darshan P. Patel,
  • Tung-Chin Hsieh

摘要

Purpose of the Review

Erectile dysfunction (ED) is a highly prevalent disease, affecting over 24% of men in the United States. Factors such as privacy and accessibility often act as barriers to care for patients. With the emergence of telemedicine, direct-to-consumer (DTC) platforms have become popular avenues for patients to seek care. These platforms are especially attractive to patients with ED due to their promises of providing discrete and convenient care. Phosphodiesterase type 5 (PDE5) inhibitors remain the most commonly prescribed therapy for ED. This review evaluates recent literature over the past five years to better understand the economics of PDE5 inhibitors offered through DTC platforms.

Recent Findings

Studies have shown that while DTC companies offer convenience, these medications are offered at a significantly marked up price compared to more conventional means, such as an in-person clinical visit and brick and mortar pharmacies.

Summary

While DTC platforms offer a promising model for improving access to ED care, their economic trade-offs and clinical limitations must be considered. Ongoing research and transparent pricing are needed to ensure that all patients with ED can make informed choices that best meet their clinical and economic needs.